Ionis and AstraZeneca share disappointing Phase 3 data for eplontersen
Ionis Pharmaceuticals (NASDAQ:IONS) and its development partner AstraZeneca (NYSE:AZN) announced today that their Phase 3 CARDIO-TTRansform clinical trial evaluating eplontersen did not meet its primary efficacy endpoint.










